DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development Image Credits: Atomwise. Continue reading -> WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> WHO Board Hears Need For Palliative Care, Children Neglected By Medical Research 06/02/2019 Catherine Saez The World Health Organization Executive Board last week heard about what the lack of access to medicines and other health services has meant in real life. These ranged from the heart-wrenching story of a baby girl needing and getting pain-killing medication to ease her life and passing to bring attention to the need for palliative care, to millions of children not getting the treatment they need to treat tuberculosis or heart diseases. Continue reading -> New Funding Partnership To Develop Innovative Drugs For Leishmaniasis 05/02/2019 David Branigan Wellcome has committed to provide more than £10 million to the Drugs for Neglected Diseases initiative (DNDi) over three years to develop new oral treatments for leishmaniasis, a devastating parasitic disease that primarily affects some of the world’s poorest people. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO-led Fair Pricing Forum Gathers Diverse Groups To Improve Drug Access 11/04/2019 Elaine Ruth Fletcher A diverse group of civil society, industry and government representatives convened today at the WHO-led 2nd Fair Pricing Forum in Johannesburg, South Africa, in the quest for new solutions that can unlock people’s access to desperately needed drugs at more affordable prices. Image Credits: Allison Colbert, Yannis Natsis. Continue reading -> GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> WHO Board Hears Need For Palliative Care, Children Neglected By Medical Research 06/02/2019 Catherine Saez The World Health Organization Executive Board last week heard about what the lack of access to medicines and other health services has meant in real life. These ranged from the heart-wrenching story of a baby girl needing and getting pain-killing medication to ease her life and passing to bring attention to the need for palliative care, to millions of children not getting the treatment they need to treat tuberculosis or heart diseases. Continue reading -> New Funding Partnership To Develop Innovative Drugs For Leishmaniasis 05/02/2019 David Branigan Wellcome has committed to provide more than £10 million to the Drugs for Neglected Diseases initiative (DNDi) over three years to develop new oral treatments for leishmaniasis, a devastating parasitic disease that primarily affects some of the world’s poorest people. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
GARDP Set Up As Independent Legal Entity 02/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading -> The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> WHO Board Hears Need For Palliative Care, Children Neglected By Medical Research 06/02/2019 Catherine Saez The World Health Organization Executive Board last week heard about what the lack of access to medicines and other health services has meant in real life. These ranged from the heart-wrenching story of a baby girl needing and getting pain-killing medication to ease her life and passing to bring attention to the need for palliative care, to millions of children not getting the treatment they need to treat tuberculosis or heart diseases. Continue reading -> New Funding Partnership To Develop Innovative Drugs For Leishmaniasis 05/02/2019 David Branigan Wellcome has committed to provide more than £10 million to the Drugs for Neglected Diseases initiative (DNDi) over three years to develop new oral treatments for leishmaniasis, a devastating parasitic disease that primarily affects some of the world’s poorest people. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Economist AMR Summit: “Broadening” Stakeholders To Strengthen Call To Action 27/03/2019 David Branigan A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading -> DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> WHO Board Hears Need For Palliative Care, Children Neglected By Medical Research 06/02/2019 Catherine Saez The World Health Organization Executive Board last week heard about what the lack of access to medicines and other health services has meant in real life. These ranged from the heart-wrenching story of a baby girl needing and getting pain-killing medication to ease her life and passing to bring attention to the need for palliative care, to millions of children not getting the treatment they need to treat tuberculosis or heart diseases. Continue reading -> New Funding Partnership To Develop Innovative Drugs For Leishmaniasis 05/02/2019 David Branigan Wellcome has committed to provide more than £10 million to the Drugs for Neglected Diseases initiative (DNDi) over three years to develop new oral treatments for leishmaniasis, a devastating parasitic disease that primarily affects some of the world’s poorest people. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
DNDi-led Study Finds Safer, Shorter Treatment For Debilitating Chagas Disease 15/03/2019 Divya Schlesinger Severe side effects make the current course of prolonged drug treatment difficult for many patients with Chagas disease, but a Phase II clinical trial in Bolivia may have found an alternative treatment that is both quicker and significantly safer. Image Credits: Ana Ferreira/DNDi. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> WHO Board Hears Need For Palliative Care, Children Neglected By Medical Research 06/02/2019 Catherine Saez The World Health Organization Executive Board last week heard about what the lack of access to medicines and other health services has meant in real life. These ranged from the heart-wrenching story of a baby girl needing and getting pain-killing medication to ease her life and passing to bring attention to the need for palliative care, to millions of children not getting the treatment they need to treat tuberculosis or heart diseases. Continue reading -> New Funding Partnership To Develop Innovative Drugs For Leishmaniasis 05/02/2019 David Branigan Wellcome has committed to provide more than £10 million to the Drugs for Neglected Diseases initiative (DNDi) over three years to develop new oral treatments for leishmaniasis, a devastating parasitic disease that primarily affects some of the world’s poorest people. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> WHO Board Hears Need For Palliative Care, Children Neglected By Medical Research 06/02/2019 Catherine Saez The World Health Organization Executive Board last week heard about what the lack of access to medicines and other health services has meant in real life. These ranged from the heart-wrenching story of a baby girl needing and getting pain-killing medication to ease her life and passing to bring attention to the need for palliative care, to millions of children not getting the treatment they need to treat tuberculosis or heart diseases. Continue reading -> New Funding Partnership To Develop Innovative Drugs For Leishmaniasis 05/02/2019 David Branigan Wellcome has committed to provide more than £10 million to the Drugs for Neglected Diseases initiative (DNDi) over three years to develop new oral treatments for leishmaniasis, a devastating parasitic disease that primarily affects some of the world’s poorest people. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> WHO Board Hears Need For Palliative Care, Children Neglected By Medical Research 06/02/2019 Catherine Saez The World Health Organization Executive Board last week heard about what the lack of access to medicines and other health services has meant in real life. These ranged from the heart-wrenching story of a baby girl needing and getting pain-killing medication to ease her life and passing to bring attention to the need for palliative care, to millions of children not getting the treatment they need to treat tuberculosis or heart diseases. Continue reading -> New Funding Partnership To Develop Innovative Drugs For Leishmaniasis 05/02/2019 David Branigan Wellcome has committed to provide more than £10 million to the Drugs for Neglected Diseases initiative (DNDi) over three years to develop new oral treatments for leishmaniasis, a devastating parasitic disease that primarily affects some of the world’s poorest people. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Board Hears Need For Palliative Care, Children Neglected By Medical Research 06/02/2019 Catherine Saez The World Health Organization Executive Board last week heard about what the lack of access to medicines and other health services has meant in real life. These ranged from the heart-wrenching story of a baby girl needing and getting pain-killing medication to ease her life and passing to bring attention to the need for palliative care, to millions of children not getting the treatment they need to treat tuberculosis or heart diseases. Continue reading -> New Funding Partnership To Develop Innovative Drugs For Leishmaniasis 05/02/2019 David Branigan Wellcome has committed to provide more than £10 million to the Drugs for Neglected Diseases initiative (DNDi) over three years to develop new oral treatments for leishmaniasis, a devastating parasitic disease that primarily affects some of the world’s poorest people. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Funding Partnership To Develop Innovative Drugs For Leishmaniasis 05/02/2019 David Branigan Wellcome has committed to provide more than £10 million to the Drugs for Neglected Diseases initiative (DNDi) over three years to develop new oral treatments for leishmaniasis, a devastating parasitic disease that primarily affects some of the world’s poorest people. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> Posts navigation Older postsNewer posts